Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Tuan Vu; Andreas Meisel; Renato Mantegazza; Djillali Annane; Masahisa Katsuno; Rasha Aguzzi; Ahmed Enayetallah; Kathleen N Beasley; Nishi Rampal; James F Howard Jr

doi:10.1007/s40120-023-00514-4

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurol Ther. 2023 Oct;12(5):1435-1438. doi: 10.1007/s40120-023-00514-4. Epub 2023 Jun 23.

Authors

Affiliations

¹ University of South Florida Morsani College of Medicine, Tampa, FL, USA. [email protected].
² Charité Universitätsmedizin Berlin, Berlin, Germany.
³ Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
⁴ Hôpital Raymond Poincaré, University of Versailles, Garches, France.
⁵ Nagoya University Graduate School of Medicine, Nagoya, Japan.
⁶ Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
⁷ The University of North Carolina, Chapel Hill, NC, USA.

Abstract

This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).

Keywords: Anti-AChR antibody; Complement; Monoclonal antibody; Myasthenia gravis; Patient-centered outcomes; Ravulizumab.